ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03681431
Recruitment Status : Active, not recruiting
First Posted : September 24, 2018
Last Update Posted : September 24, 2018
Sponsor:
Information provided by (Responsible Party):
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Brief Summary:
The clinical trial is designed as a phase II, crossover clinical trial. It will be carried out in healthy volunteers, who will receive two different antibiotic regimen based on ceftriaxone. One of the regimens had shown clinical effectiveness in this scenario, but it is not suitable for OPAT programs. In the other hand, a new treatment schema useful in OPAT programs is proposed, but there is still a lack of pharmacokinetic data to support it. The plasma drug concentrations will be measured in both cases, comparing the minimal drug concentration observed and the pharmacokinetic profiles of the two regimens.

Condition or disease Intervention/treatment Phase
Infectious Endocarditis Drug: Ceftriaxone 4g/ 24h Drug: Ceftriaxone 2g/ 12h Phase 2

Detailed Description:

Infective endocarditis (IE) is an uncommon but virulent infection disease. One of the most frequent etiology for this infection is Enterococcus faecalis. IE treatment is difficult due to the characteristics of the infection itself, the bacterial species and the frequent comorbidities of the patients. A bactericidal antimicrobial treatment is mandatory for the resolution of this disease, but most antibiotics do not exhibit this effect against E. faecalis and have prompted the combination of an aminoglycoside and a cell-wall active agent (generally a β-lactam) as the standard treatment. This is a lengthy treatment (4-6 weeks) and its primary side effect is nephrotoxicity. Furthermore, aminoglycoside resistant strain's rates are increasing in USA and Europe, getting more complicated to establish an effective antibiotic regimen. Nowadays, patients with E. faecalis IE are old and often have significant underlying comorbidities with an increased risk of developing nephrotoxicity with aminoglycoside treatment. For this reason, and for the relevance of high-level aminoglycoside-resistant strains, some alternatives have been explored. A double β-lactam regimen is an option, despite the intrinsically resistance of E. faecalis to cephalosporins. The most studied combination is a regimen based on ampicillin plus ceftriaxone, which has shown a synergistic effect in vitro. This combination is as effective as ampicillin plus gentamycin, but with lower nephrotoxicity. Those patients need at least 4-6 weeks of treatment with a prolonged hospitalization. However, after 2 week of treatment some patients are clinically stabilized and could be benefit of an outpatient parenteral antibiotic therapy (OPAT) program. For that purpose, it is essential to design a treatment regimen, which ensures the effectiveness and safety of the treatment, based on stability and pharmacokinetic and pharmacodynamics (PK/PD) studies of the administered drugs. Furthermore, the logistic and schedule should be simple enough to enable the inclusion in an OPAT program. In order to design an antibiotic regimen suitable for OPAT programs and as effective as the standard therapies for E. faecalis IE, we decided to start clinical trial.

The clinical trial is designed as a phase II, crossover clinical trial. It will be carried out in healthy volunteers, who will receive two different antibiotic regimen based on ceftriaxone. One of the regimens had shown clinical effectiveness in this scenario, but it is not suitable for OPAT programs. In the other hand, a new treatment schema useful in OPAT programs is proposed, but there is still a lack of pharmacokinetic data to support it. The plasma drug concentrations will be measured in both cases, comparing the minimal drug concentration observed and the pharmacokinetic profiles of the two regimens.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: A phase II, single-centre, open, non-randomized, cross-over, clinical trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial to Evaluate an Antibiotic Regimen Pharmacokinetic Applicable to Outpatient Parenteral Antimicrobial Therapy in Enterococcus Faecalis Infective Endocarditis
Actual Study Start Date : April 23, 2018
Estimated Primary Completion Date : April 23, 2019
Estimated Study Completion Date : May 23, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ceftriaxone 4g/ 24h
Single intravenous dose of Ceftriaxone 4g/ 24h
Drug: Ceftriaxone 4g/ 24h
Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.

Active Comparator: Ceftriaxone 2g/ 12h
Two intravenous doses of Ceftriaxone 2g/ 12h
Drug: Ceftriaxone 2g/ 12h
Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.




Primary Outcome Measures :
  1. Serum levels after 24 hours [ Time Frame: 24 hours ]
    To determinate whether 24 hours after the administration of 4 grams of ceftriaxone in a single short infusion, serums levels would be higher than 5 micrograms per millilitre


Secondary Outcome Measures :
  1. AUC 24 hours [ Time Frame: 24 hours ]
    To compare the 24 hours area under the curve (AUC) after the administration of 4 grams of ceftriaxone in a single short infusion and the administration of 2 grams of ceftriaxone in a two short infusions separated for 12 hours.

  2. Plasma Clearance [ Time Frame: 24 hours ]
    To determinate ceftriaxone plasma clearance after the administration of 4 grams of ceftriaxone in a single short infusion.

  3. Elimination Half-life [ Time Frame: 24 hours ]
    To determinate ceftriaxone elimination half-life after the administration of 4 grams of ceftriaxone in a single short infusion.

  4. Volume of Distribution [ Time Frame: 24 hours ]
    To determinate ceftriaxone volume of distribution after the administration of 4 grams of ceftriaxone in a single short infusion.

  5. Maximum Plasma Concentration [ Time Frame: 24 hours ]
    To determinate ceftriaxone maximum plasma concentration after the administration of 4 grams of ceftriaxone in a single short infusion.

  6. Safety: Number, frequency and importance of adverse reactions. [ Time Frame: 1 month ]
    To determinate the safety (number, frequency and importance of adverse reactions) of the administration of 4 grams of ceftriaxone in a single short infusion



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male and female adults subjects.
  2. Weight between 40 and 105 kilograms, both included, and body mass index lower than 34 kilograms per square meter.
  3. The subject (or his/her "trusted representative") must have given his/her informed and signed consent approved by an Ethical Committee.
  4. The subject must have normal analytical values or abnormal without clinical significance of biochemical parameters, liver and kidney function panel test, hemogram and album level. A medical check will be run by workers of Infectious Diseases Department.
  5. The subject must have a normal physical examination or abnormal without clinical significance. A medical check will be run by workers of Infectious Diseases Department.
  6. The medication taken usually by the subjects will be check by the Pharmacy Department in order to find possible interactions with ceftriaxone.

Exclusion Criteria:

  1. Subjects with clinically significant abnormalities in laboratory test or physical exploration. A medical check will be run by workers of Infectious Diseases Department.
  2. Subjects undergoing an active infection find at the screening.
  3. Subjects with any clinical or surgery condition which contraindicate his/her inclusion, check by workers of Infectious Diseases Department.
  4. Subjects who has received treatment with cephalosporins 21 days before the trial starts or during the trial (apart from the protocol treatment).
  5. Subjects hypersensitive or allergic to cephalosporines or penicillins.
  6. Subjects undergoing chronic or acute cutaneous diseases which prevent the treatment administration.
  7. Subjects not giving his/her informed and signed consent approved by an Ethical Committee.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03681431


Locations
Spain
University Hospital Virgen del Rocio
Sevilla, Spain, 41013
Sponsors and Collaborators
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Investigators
Principal Investigator: Maria Victoria H Gil Navarro University Hospital Virgen del Rocio/ Institute of Biomedicine of Seville
  Study Documents (Full-Text)

Documents provided by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla:
Study Protocol  [PDF] January 11, 2018


Responsible Party: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
ClinicalTrials.gov Identifier: NCT03681431     History of Changes
Other Study ID Numbers: ENDOKINETIC-CEF
First Posted: September 24, 2018    Key Record Dates
Last Update Posted: September 24, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla:
Pharmacokinetic
Ceftriaxone
Enterococcus faecalis
Infectious Endocarditis

Additional relevant MeSH terms:
Communicable Diseases
Infection
Endocarditis
Endocarditis, Bacterial
Endocarditis, Subacute Bacterial
Heart Diseases
Cardiovascular Diseases
Bacterial Infections
Cardiovascular Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Anti-Bacterial Agents
Ceftriaxone
Anti-Infective Agents